News Sentiment

CRBP sentiment intelligence

Corbus Pharmaceuticals Holding news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.01 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 9

high-authority source matches

Trend context Trend inactive

-6.9% over one week, +9.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -6.9% Price reacting lower
Trend fit Trend inactive 9.1% over four weeks
Fair value -47.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 41
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
MarketWatch 7
Market source 7
TradingView 6
simplywall.st 5
GlobeNewswire 4
MarketBeat 3
Quiver Quantitative 3

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 13
Analyst action 3
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 2.39% to $9.01 on Friday, despite a generally poor trading session for the broader market where both the NASDAQ Composite and Dow Jones Industrial Average declined. This increase broke a four-day losing streak for

Tone
Positive 70/100
Event
Market update
Published
17 Jul 2026 17:20
Source
MarketWatch
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price decline by 2.33% to $8.80, marking its fourth consecutive day of losses. This occurred during a general market downturn, with both the NASDAQ Composite and Dow Jones Industrial Average also falling. Despite the daily

Tone
Negative 38/100
Event
Market update
Published
16 Jul 2026 17:19
Source
MarketWatch
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 6.61% to $9.04 on Monday, breaking a four-day winning streak. This underperformance occurred during an overall poor trading session, with the NASDAQ Composite Index falling 1.55% and the Dow Jones Industrial Average decli

Tone
Negative 28/100
Event
Market update
Published
13 Jul 2026 17:21
Source
MarketWatch
TradingView Direct company coverage

Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP

This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from TradingView, specifically focusing on its enterprise value to EBIT forward. The content appears to be a financial data page rather than a traditional article, offering variou

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 12:39
Source
TradingView
The Globe and Mail Direct company coverage

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings extensive experience in solid tumor drug development, particularly with antibody-drug conjugates (ADCs) and HPV-driven oncolog

Tone
Positive 71/100
Event
Market update
Published
11 Jul 2026 04:11
Source
The Globe and Mail
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock increase by 1.81% on Wednesday, closing at $9.55, despite the broader market showing mixed results. The NASDAQ Composite Index rose while the Dow Jones Industrial Average fell. This marks the second consecutive day of gain

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 17:17
Source
MarketWatch
citybiz Direct company coverage

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer

Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer, strengthening its oncology drug development team. This appointment comes as Corbus prepares to advance multiple oncology and obesity programs, including the registrational TEMPO-1 study f

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 17:40
Source
citybiz
www.marketscreener.com Direct company coverage

Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. has announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in the pharmaceutical industry, having previously served as Chief Medical Officer at Protara Thera

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 15:40
Source
www.marketscreener.com
Investing.com Canada Direct company coverage

Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, bringing over 20 years of pharmaceutical industry experience to the company. Dr. Nicacio previously held significant roles at Protara Therapeutics, Seagen, A

Tone
Positive 65/100
Event
Market update
Published
06 Jul 2026 12:25
Source
Investing.com Canada
Stock Titan Direct company coverage

Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines

Corbus Pharmaceuticals has appointed Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026, with a compensation package including a $545,000 base salary and $2.1 million in equity awards. The company also outlined key clinical development milest

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:16
Source
Stock Titan
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock rose 1.98% on Thursday to $9.25, amidst a mixed trading session where the Dow Jones Industrial Average gained 1.14% and the NASDAQ Composite Index fell 0.80%. Despite the daily gains, the stock underperformed compared to some comp

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 16:17
Source
MarketWatch
MarketWatch Direct company coverage

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) fell 3.30% on Wednesday, closing at $9.07. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and the Dow Jones Industrial Average also declining. The stock's drop

Tone
Negative 32/100
Event
Market update
Published
01 Jul 2026 17:19
Source
MarketWatch
Stock Traders Daily Direct company coverage

(CRBP) Risk Channels and Responsive Allocation

This article provides a detailed analysis of Corbus Pharmaceuticals Holdings Inc. (CRBP), highlighting near and mid-term strong sentiment but a weak long-term outlook. It outlines several AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with s

Tone
Positive 64/100
Event
Guidance
Published
30 Jun 2026 16:20
Source
Stock Traders Daily
marketscreener.com Direct company coverage

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark

Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP) has been added to the Russell 2000 Value Benchmark, effective June 29, 2026. This news follows a previous announcement of its inclusion in the Russell 3000E Index. The company is focused on oncology and obesity, with a pipeli

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 14:41
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – BOATS:CRBP

This article provides the enterprise value to EBIT forward for Corbus Pharmaceuticals Holdings, Inc. (CRBP) within the Blue Ocean Alternative Trade System (BOATS) on TradingView. It indicates that the market was closed at the time of viewing and presents financial data provided b

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:39
Source
TradingView
TradingView Direct company coverage

CRBP Forecast — Price Target — Prediction for 2027

The article provides a forecast for Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock, including current price, historical performance, analyst price targets, and key financial data. It highlights that analysts have a max estimated price target of $52.00 and a min of $17.00. The

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP

This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, a platform offering market data and analysis tools.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP

This article provides financial information for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), specifically its forward price-to-sales ratio. The content appears to be a financial data point from TradingView, indicating that the market is currently closed for this stock.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:10
Source
TradingView